Serum Proteomic Profiles of Patients with High and Low Risk of Endometrial Cancer Recurrence.
endometrial cancer
high-risk endometrial cancer
mass spectrometry
proteomics
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
25 Sep 2023
25 Sep 2023
Historique:
received:
01
08
2023
revised:
14
09
2023
accepted:
20
09
2023
medline:
1
11
2023
pubmed:
14
10
2023
entrez:
14
10
2023
Statut:
epublish
Résumé
Endometrial cancer is the most common gynecological cancer worldwide. Classifying endometrial cancer into low- or high-risk groups based on the following features is recommended: tumor grade, lymphovascular space invasion, myometrial involvement, and non-endometrioid histology. Despite the recent progress in molecular profiling of endometrial cancer, a substantial group of patients are misclassified based on the current criteria. This study aimed to identify proteins that could be used as biomarkers for the stratification of endometrial cancer patients into low- or high-risk groups. The proteomic analysis of serum samples from endometrial cancer patients was performed using matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS). The data were then analyzed using chemometric algorithms to identify potential biomarkers. Nineteen precursor ions were identified as fragments of eighteen proteins which included (1) connective tissue matrix proteins, (2) cytoskeletal proteins, and (3) innate immune system molecules and stress proteins. These biomarkers could be used to stratify the high- and low-risk patients, thus enabling more precise treatment decisions.
Identifiants
pubmed: 37833976
pii: ijms241914528
doi: 10.3390/ijms241914528
pmc: PMC10572223
pii:
doi:
Substances chimiques
Biomarkers
0
Proteins
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Front Immunol. 2021 Nov 30;12:796493
pubmed: 34917098
Cancers (Basel). 2021 Oct 05;13(19):
pubmed: 34638469
Nutrients. 2021 Oct 28;13(11):
pubmed: 34836106
Int J Biol Sci. 2020 Apr 27;16(12):2014-2028
pubmed: 32549750
EBioMedicine. 2023 Jun;92:104595
pubmed: 37146405
BMC Cancer. 2009 Dec 22;9:460
pubmed: 20028502
Biochim Biophys Acta Proteins Proteom. 2017 Jul;1865(7):846-857
pubmed: 27784647
J Cancer. 2019 May 21;10(10):2220-2228
pubmed: 31258725
Gynecol Oncol. 2006 Nov;103(2):714-8
pubmed: 16740298
Br J Cancer. 2021 Jul;125(2):265-276
pubmed: 33981016
J Clin Oncol. 2020 Oct 10;38(29):3388-3397
pubmed: 32749941
BMC Cancer. 2008 Jan 28;8:25
pubmed: 18226209
Cancers (Basel). 2020 Jan 18;12(1):
pubmed: 31963677
J Clin Invest. 2009 Jul;119(7):1763-71
pubmed: 19587451
BMC Cancer. 2017 Jul 6;17(1):472
pubmed: 28683725
J Obstet Gynaecol. 2016;36(3):353-8
pubmed: 26470941
Lancet Oncol. 2019 Sep;20(9):1273-1285
pubmed: 31345626
Nucleic Acids Res. 2023 Jan 6;51(D1):D523-D531
pubmed: 36408920
Dev Cell. 2019 May 6;49(3):361-374
pubmed: 31063755
Mod Pathol. 2015 Jun;28(6):836-44
pubmed: 25720322
J Clin Med. 2023 Jan 09;12(2):
pubmed: 36675462
Front Cell Dev Biol. 2021 Apr 08;9:606149
pubmed: 33898417
Cancer Cell Int. 2019 Nov 15;19:300
pubmed: 31787848
Int J Gynecol Cancer. 2021 Jan;31(1):12-39
pubmed: 33397713
Adv Exp Med Biol. 2008;644:124-31
pubmed: 19209818
J Natl Cancer Inst. 2014 Dec 12;107(1):402
pubmed: 25505230
N Engl J Med. 2023 Jun 8;388(23):2145-2158
pubmed: 36972026
JAMA Intern Med. 2018 Sep 1;178(9):1210-1222
pubmed: 30083701
Lancet. 2022 Apr 9;399(10333):1412-1428
pubmed: 35397864
Adv Biol (Weinh). 2022 Dec;6(12):e2200197
pubmed: 36084257